Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Sarcoma 3Neoplasm Metastasis 3Colorectal Neoplasms 3Sarcoma, Ewing 2Ovarian Neoplasms 2Carcinoid Tumor 2Breast Neoplasms 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Recurrence 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Lymphoma 1Insulin-Like Growth Factor I, Resistance To 1Hemangiosarcoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Askin Tumor 1Adenoma, Islet Cell 1

Interventions

Temozolomide 6Capecitabine 4Everolimus 3Thalidomide 2Sunitinib 2Streptozocin 2Octreotide 2Injections 2Fluorouracil 2surufatinib 1sargramostim 1recombinant interferon alpha 2b-like protein 1nimotuzumab 1motesanib diphosphate 1montanide ISA 51 1lutetium Lu 177 dotatate 1incomplete Freund's adjuvant 1ibrutinib 1ganitumab 1cabozantinib 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1Tegafur 1Specimen Handling 1PM 01183 1Metformin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenoma, Islet Cell × ganitumab × Clear all
NCT01024387 2018-03-08

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 7 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡